Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17727034 | 0.94 | ALDH1A1 (0.35) | SMN1; SMN2HSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL17727009 | 0.87 | USP2 (0.34) | SMN1; SMN2HSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL13750213 | 0.82 | ALDH1A1 (0.36) | SMN1; SMN2HSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL17727017 | 0.81 | SMN1; SMN2 (0.36) | SMN1; SMN2HSD17B10ALDH1A1MAPTTSHR | |
| SCHEMBL17727007 | 0.79 | — | — | |
| SCHEMBL4318918 | 0.77 | RAB9A (0.58) | SMN1; SMN2HSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL9836459 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2HSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL9175656 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2HSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL11375936 | 0.75 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10ALDH1A1NPC1RAB9A | |
| SCHEMBL4317157 | 0.74 | NPC1 (0.40) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118829067-A | Laminate, method for producing same, and use of laminate | DIC株式会社 | 2024-10-22 | — | — | CN | disclosed |
| EP-3018137-B1 | AZOLE SILANE COMPOUND, SURFACE TREATMENT SOLUTION, SURFACE TREATMENT METHOD, AND USE THEREOF | SHIKOKU CHEM (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-9688704-B2 | Azole silane compound, surface treatment solution, surface treatment method, and use thereof | SHIKOKU CHEMICALS CORPORATION (JP) | 2017-06-27 | — | — | US | disclosed |
| US-20160368935-A1 | AZOLE SILANE COMPOUND, SURFACE TREATMENT SOLUTION, SURFACE TREATMENT METHOD, AND USE THEREOF | SHIKOKU CHEMICALS CORPORATION (JP) | 2016-12-22 | — | — | US | disclosed |
| EP-3018137-A1 | AZOLE SILANE COMPOUND, SURFACE TREATMENT SOLUTION, SURFACE TREATMENT METHOD, AND USE THEREOF | Shikoku Chemicals Corporation (JP) | 2016-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368935-A1 | AZOLE SILANE COMPOUND, SURFACE TREATMENT SOLUTION, SURFACE TREATMENT METHOD, AND USE THEREOF | ICAM1, SULT1A1, STIM1 | SMN1; SMN2 4197/4885HSD17B10 1413/4885ALDH1A1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.